Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Vivos Therapeutics (VVOS) Other Operating Expenses (2020 - 2025)

Historic Other Operating Expenses for Vivos Therapeutics (VVOS) over the last 6 years, with Q3 2025 value amounting to -$5.5 million.

  • Vivos Therapeutics' Other Operating Expenses fell 8980.23% to -$5.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.0 million, marking a year-over-year decrease of 17438.86%. This contributed to the annual value of $1.7 million for FY2024, which is 3118.97% down from last year.
  • Latest data reveals that Vivos Therapeutics reported Other Operating Expenses of -$5.5 million as of Q3 2025, which was down 8980.23% from -$5.2 million recorded in Q2 2025.
  • Vivos Therapeutics' 5-year Other Operating Expenses high stood at $2.3 million for Q4 2021, and its period low was -$5.5 million during Q3 2025.
  • In the last 5 years, Vivos Therapeutics' Other Operating Expenses had a median value of $691000.0 in 2023 and averaged -$10241.9.
  • As far as peak fluctuations go, Vivos Therapeutics' Other Operating Expenses skyrocketed by 36135.97% in 2021, and later tumbled by 51722.14% in 2024.
  • Vivos Therapeutics' Other Operating Expenses (Quarter) stood at $2.3 million in 2021, then plummeted by 46.69% to $1.2 million in 2022, then crashed by 54.66% to $555000.0 in 2023, then crashed by 35.86% to $356000.0 in 2024, then plummeted by 1637.08% to -$5.5 million in 2025.
  • Its Other Operating Expenses stands at -$5.5 million for Q3 2025, versus -$5.2 million for Q2 2025 and $335000.0 for Q1 2025.